Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lot-to-lot consistency and active comparator study of V116 in adults 18 to 49 years of age
2022-000265-41Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of participants with solicited injection-site adverse events. Started Jul 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2022-000265-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000265-41.